Search results for "edema"

showing 10 items of 625 documents

Hereditary angioedema in a single family with specific mutations in both plasminogen and SERPING1 genes

2019

BACKGROUND Hereditary angioedema (HAE) is a group of genetic diseases characterized by recurrent, painful and potentially lethal tissue swelling. The most common form results from mutations in the SERPING1 gene, leading to reduced function of complement 1 inhibitor (C1-INH). Rarer forms with normal C1-INH may arise from mutations in the coagulation factor F12 gene, but mostly the genetic background is unknown. Recently, a novel HAE mutation in the plasminogen (PLG) gene was shown. PATIENTS AND METHODS We analyzed the various clinical manifestations of HAE in 14 related patients using clinical data, biochemical analysis for C1-INH and C4 as well as gene sequencing. RESULTS Patients' symptoms…

AdultMaleAdolescentMutation MissenseDermatologymedicine.disease_causeYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineTonguemedicineHumansFamilyChildGeneSingle familyMutationGastrointestinal tractbusiness.industryAngioedemas HereditaryPlasminogenMiddle Agedmedicine.diseasePhenotype3. Good healthPhenotypemedicine.anatomical_structureCoagulationChild PreschoolMutationHereditary angioedemaImmunologyFemalebusinessComplement C1 Inhibitor ProteinJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Pain and swelling after periapical surgery related to oral hygiene and smoking.

2007

Objectives To evaluate pain and swelling during the first week after periapical surgery and its relation to patient age, gender, oral hygiene, and smoking. Study design One hundred two patients (31 men and 71 women) with a mean age of 40.2 years underwent periapical surgery. Age, gender, and oral hygiene and cigarette smoking before and during the postoperative course were noted. Pain and swelling scores were recorded on a descriptive 4-point scale at 2, 6, and 12 hours after surgery, and each day thereafter for 1 week. The data were statistically evaluated for significant differences. Results The highest intensity of pain occurred during the first 48 hours, and swelling peaked on the secon…

AdultMaleAdolescentOral Surgical ProceduresOral hygieneStatistics NonparametricSex FactorsCigarette smokingPatient ageEdemamedicineEdemaHumansIn patientProspective StudiesGeneral DentistryAgedAnalysis of VariancePain Postoperativebusiness.industryPeriapical DiseasesSmokingAge FactorsMean ageOral HygieneOtorhinolaryngologyAnesthesiaRetrograde ObturationSurgeryFemaleOral SurgerySwellingmedicine.symptombusinessPeriapical surgeryOral surgery, oral medicine, oral pathology, oral radiology, and endodontics
researchProduct

High-Concentration Liquid Prednisolone Formula: Filling a Therapeutic Niche in Severe Acute Attacks of Urticaria and Angioedema.

2015

<b><i>Background/Aims:</i></b> According to current guidelines, the emergency kit for patients with severe urticaria and/or angioedema should include a corticosteroid with a prednisolone-equivalent of 50-100 mg. Since severe dysphagia may occur in anaphylaxis, liquid corticosteroids are advantageous. Presently, only liquid preparations with less than 100 mg prednisolone equivalent are available worldwide. <b><i>Methods:</i></b> We prepared a highly concentrated liquid prednisolone formula for oral administration (1 or 5 mg prednisolone per ml). We observed efficacy and safety of 100 mg or >250 mg liquid oral prednisolone in comparison to in…

AdultMaleAdolescentUrticariaPhysiologymedicine.drug_classmedicine.medical_treatmentPrednisoloneAnti-Inflammatory AgentsAdministration OralDermatologyDosage form030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineOral administrationmedicineHumansAngioedemaAgedPharmacologyHigh concentrationDosage FormsAngioedemabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemIntravenous therapyAnesthesiaPrednisoloneCorticosteroidFemalemedicine.symptombusinessAnaphylaxismedicine.drugSkin pharmacology and physiology
researchProduct

Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema.

2008

Background:  Skin swellings are the most frequent symptoms in hereditary angio-oedema (HAE) arising out of C1-inhibitor (C1-INH) deficiency. They may be painful and impact daily activities of patients. Detailed clinical data concerning the treatment of skin swellings by C1-INH concentrate have not been reported yet. Methods:  From 1976 through 2007, a total of 2104 skin-swelling attacks in 47 patients with HAE were treated with the C1-INH concentrate. Time to relief and duration of the swellings were documented during personal interviews using standardized questionnaires. The results were compared with 9046 untreated skin swellings in the same patients. Results:  The first clinical sign of …

AdultMaleAllergymedicine.medical_specialtyHereditary angio-oedemaAdolescentImmunologyC1-inhibitorImmunopathologyImmunology and AllergyMedicineHumansIn patientProspective StudiesChildAgedRetrospective StudiesSkinbiologybusiness.industryAngioedemas HereditaryDrug administrationMiddle Agedmedicine.diseaseTrunkSurgerybiology.proteinFemaleLaryngeal oedemabusinessComplement C1 Inhibitor ProteinAllergy
researchProduct

Occurrence of Cerebral Venous Sinus Thrombosis in Patients with Presumed Idiopathic Intracranial Hypertension

2005

Purpose To report the rate of occurrence of cerebral venous sinus thrombosis (CVST) in patients with presumed idiopathic intracranial hypertension (IIH). Design Retrospective chart review. Participants All patients diagnosed with papilledema from November 1, 2002, through October 31, 2003, at 3 tertiary care neuro-ophthalmology centers. Methods Consecutive patients with a diagnosis of papilledema from 3 tertiary care neuro-ophthalmology centers were identified. Patients with space-occupying lesions, hydrocephalus, or meningitis were excluded. The remaining patients were evaluated with lumbar puncture, magnetic resonance imaging (MRI), and magnetic resonance venography (MRV). Main Outcome Me…

AdultMaleCerebral veinsmedicine.medical_specialtyAdolescentMagnetic resonance angiographySinus Thrombosis IntracranialCerebrospinal Fluid PressureRisk FactorsmedicineHumansCerebral venous sinus thrombosisChildPapilledemaAgedRetrospective StudiesPseudotumor Cerebrimedicine.diagnostic_testLumbar puncturebusiness.industryPhlebographymedicine.diseaseCerebral VeinsHydrocephalusSurgeryOphthalmologyVenous thrombosisFemaleCerebrospinal fluid pressureIntracranial Thrombosismedicine.symptombusinessMagnetic Resonance AngiographyPapilledemaOphthalmology
researchProduct

A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor.

2011

In hereditary angioedema with normal C1-inhibitor two different missense mutations of codon p.Thr328* in the coagulation factor 12 gene have been reported in some families. In this study a novel factor 12 gene mutation, the deletion of 72 base pairs (bp) (c.971_1018+24del72*), was identified in a family of Turkish origin, in two sisters with recurrent skin swellings and abdominal pain attacks and in their symptom-free father. This deletion caused a loss of 48 bp of exon 9 (coding amino acids 324* to 340*) in addition to 24 bp of intron 9, including the authentic donor splice site of exon 9. The large deletion of 72 bp was located in the same F12 gene region as the missense mutations p.Thr32…

AdultMaleFactor XII DeficiencyTurkeyImmunologyDNA Mutational AnalysisMutation MissenseGene mutationmedicine.disease_causeC1-inhibitorExonImmunology and AllergyMedicineMissense mutationHumansHereditary Angioedema Type IIISequence DeletionGeneticsMutationAngioedemabiologybusiness.industryAngioedemas HereditaryExonsmedicine.diseaseMolecular biologyIntronsPedigreeHereditary angioedemaFactor XIIMutationbiology.proteinFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinClinical immunology (Orlando, Fla.)
researchProduct

Interaction of hyperalgesia and sensory loss in complex regional pain syndrome type I (CRPS I).

2008

Background: Sensory abnormalities are a key feature of Complex Regional Pain Syndrome (CRPS). In order to characterise these changes in patients suffering from acute or chronic CRPS I, we used Quantitative Sensory Testing (QST) in comparison to an age and gender matched control group. Methods: 61 patients presenting with CRPS I of the upper extremity and 56 healthy subjects were prospectively assessed using QST. The patients’ warm and cold detection thresholds (WDT; CDT), the heat and cold pain thresholds (HPT; CPT) and the occurrence of paradoxical heat sensation (PHS) were observed. Results: In acute CRPS I, patients showed warm and cold hyperalgesia, indicated by significant changes in H…

AdultMaleHot TemperatureCentral nervous systemlcsh:MedicineEdemaSensationmedicineHumansProspective Studieslcsh:ScienceAnesthesiology and Pain ManagementAgedPain MeasurementInflammationMultidisciplinarybusiness.industryNeuroscience/Sensory SystemsNeurological Disorders/Pain Managementlcsh:RSensory lossMiddle Agedmedicine.diseasePeripheralCold TemperatureReflex Sympathetic Dystrophymedicine.anatomical_structureComplex regional pain syndromeHyperalgesiaCase-Control StudiesAnesthesiaNeuropathic painHyperalgesiaFemalelcsh:Qmedicine.symptombusinessAlgorithmsResearch ArticlePLoS ONE
researchProduct

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)

2006

Background In hereditary angioedema, bradykinin is assumed to be the most important mediator of edema formation. Objective To assess whether the selective bradykinin receptor-2 antagonist Icatibant is effective in acute edema attacks of hereditary angioedema. Methods In this uncontrolled pilot study, 15 patients with 20 attacks were treated with Icatibant. The attacks were analyzed by using a standardized and validated visual analog scale measurement and compared with historical data of untreated attacks. Plasma bradykinin concentration was measured before and 4 hours after intravenous Icatibant treatment. Results Symptom intensity decreased within 4 hours after administration of Icatibant;…

AdultMaleImmunologyBradykininPilot ProjectsBradykininchemistry.chemical_compoundEcallantideIcatibantBradykinin B2 Receptor AntagonistsHumansImmunology and AllergyMedicineAngioedemaBradykinin receptorBradykinin B2 Receptor AntagonistsAngioedemabusiness.industryGenetic Diseases InbornMiddle Agedmedicine.diseasechemistryAnesthesiaAcute DiseaseHereditary angioedemaFemalemedicine.symptomB2 Bradykinin Receptorbusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

An exploratory, prospective, open-label trial of ingenol mebutate gel 0.05% for the treatment of external anogenital warts

2017

BACKGROUND Anogenital warts (AGW) can cause physical discomfort and decreased quality of life. Recent case reports suggest that ingenol mebutate gel might be an effective treatment of AGW. OBJECTIVE To explore primarily the safety, and secondarily the efficacy of ingenol mebutate gel 0.05% in patients with AGW. METHODS This was an exploratory, open-label, 1-arm trial of ingenol mebutate gel 0.05% administered up to three times to patients with AGW. Safety was assessed by occurrence and severity of local skin reactions (LSRs) and treatment-related adverse events (AEs). Efficacy was assessed by complete clearance and reduction in AGW count 14 days after last treatment, and recurrence 12 weeks…

AdultMaleIngenol Mebutate Gelmedicine.medical_specialtyPopulationPainAntineoplastic AgentsDermatologyYoung Adult030207 dermatology & venereal diseases03 medical and health sciencesBlister0302 clinical medicineQuality of lifeRecurrenceInternal medicineSkin UlcermedicineEdemaHumansEffective treatmentIn patientProspective Studies030212 general & internal medicineAdverse effecteducationAgedAnus Diseaseseducation.field_of_studybusiness.industryMiddle AgedSafety profileTreatment OutcomeInfectious DiseasesCondylomata AcuminataErythemaFemaleDiterpenesGenital Diseases MaleOpen labelbusinessGelsGenital Diseases FemaleJournal of the European Academy of Dermatology and Venereology
researchProduct

Ocular Changes in Patients With Mucopolysaccharidosis I Receiving Enzyme Replacement Therapy

2007

Objective To describe the progression of ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy. Methods Three male and five female patients with mucopolysaccharidosis I were followed up for 4 years while undergoing enzyme replacement therapy with α-L-iduronidase (Aldurazyme). Visual acuity, corneal clouding, intraocular pressure, ophthalmoscopy, and optic disc measurements were performed yearly. Results Vision remained stable in 5 patients and deteriorated by at least 2 Snellen lines in 3 patients. Deterioration in 2 of these patients was related to progressive corneal clouding. Visual acuities improved in 1 patient after bilateral penetrating keratopl…

AdultMaleIntraocular pressuremedicine.medical_specialtyVisual acuityAdolescentgenetic structuresMucopolysaccharidosis Imedicine.medical_treatmentOptic DiskVisual AcuityCorneal DiseasesIduronidaseDouble-Blind MethodOptic Nerve DiseasesMucopolysaccharidosis IHumansMedicineChildInfusions IntravenousPapilledemaIntraocular PressureCorneal transplantationbusiness.industryEnzyme replacement therapyRecombinant Proteinseye diseasesSurgeryOphthalmoscopyOphthalmologymedicine.anatomical_structureDisease ProgressionOptic nerveFemalesense organsmedicine.symptombusinessOptic discArchives of Ophthalmology
researchProduct